The Use Of Lithium In The Prophylaxis And Treatment Of
Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option
Or Hazard

J 2006

The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard

SVOBODA, Marek, Marián HAJDÚCH, Jana KLEINOVÁ, Miloš HOLÁNEK, Lenka RADOVÁ et. al.

Základní údaje

Originální název

The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard

Název česky

Použití lithia k profylaxi a léčbě chemoterapií indukované neutropenie: efektivní postup nebo hazard?

Autoři

SVOBODA, Marek (203 Česká republika, garant), Marián HAJDÚCH (203 Česká republika), Jana KLEINOVÁ (203 Česká republika), Miloš HOLÁNEK (203 Česká republika), Lenka RADOVÁ (203 Česká republika), Jana GOMBOŠOVÁ (703 Slovensko) a František FOLBER (203 Česká republika)

Vydání

Support Care Cancer, Heidelberg, Germany, Springer-Verlag, 2006, 0941-4355

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.905

Kód RIV

RIV/00216224:14110/06:00019207

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

litihum;akt kinase;chemotherapy;chemoresistance;neutropenia;

Štítky

Akt kinase, chemoresistance, chemotherapy, litihum, neutropenia

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 29. 1. 2008 01:15, prof. MUDr. Marek Svoboda, Ph.D.

Anotace

ORIG CZ

V originále

Introduction: Lithium is an antimanic agent successfully used in the treatment of patients with bipolar disorder. Even at therapeutic levels many patients experience one of the most frequent non-toxic and reversible side effect of lithium: leukocytosis. Due this effect, lithium has been used in the treatment and prophylaxis of CIN before the availability of colony-stimulating factors (CSF) and it remains as a costeffective option compared with CSF. Recently, lithium has been reported to protect cells against apoptosis via a direct inhibition of GSK-3beta and activation of Akt/PKB. Both kinases play important role in processes of primary and inducible tumor chemoresistance. Results: I. 151 MTT tests were performed for in-vitro testing of chemo-sensitivity of 53 primary tumours against cisplatin, melphalan, doxorubicin and paclitaxel with or without presence of 10mM or 2mM lithium. At the concentration of 10mM, lithium enormously increased chemoresistance of primary tumours against doxorubicin (p=0,000000453) and paclitaxel (p=0,000277692). At the concentration of 2mM the lithium significantly increases chemoresistance only against doxorubicin. There was no effect of lithium on alkylating agents. II. A retrospective analysis of clinical data of 271 patients who developed CIN and were treated by lithium carbonate (1st group) or without any treatment (2nd group) was done. Median of neutrophils counts at the initial blood counts examinations after chemotherapy was 0,9 and 0.94x109/L (1st and 2nd group respectively) and after 7 days of lithium administration was 2,71x109/L compared to 2,03x109/L at the 2nd group (p=0,15). Conclusions: This study demonstrates: I) lithium can increase chemoresistance of primary tumours against cytostatic agents and II) the effect of lithium on the neutrophils counts is disputative. Therefore there is no rationalization for the use of lithium in the treatment and prophylaxis of CIN. Acknowledgements: The work was supported by grants from The Czech T.Fox Run 2005 and IGA MZCR NR/8335-3.

Česky

Práce je pouze v anglickém jazyce.

Návaznosti

NR8335, projekt VaV

Název: Predikce chemosenzitivity / chemorezistence na cílenou protinádorovou terapii u pacientek s karcinomem prsu s prokázanou HER-2 pozitivitou, na podkladě analýzy Akt signální dráhy a sérové hladiny HER-2 receptoru

Citovat

SVOBODA, Marek, Marián HAJDÚCH, Jana KLEINOVÁ, Miloš HOLÁNEK, Lenka RADOVÁ, Jana GOMBOŠOVÁ a František FOLBER. The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard. Support Care Cancer. Heidelberg, Germany: Springer-Verlag, 2006, roč. 2006, č. 14, s. 605-606. ISSN 0941-4355.

@article{752227,
   author = {Svoboda, Marek and Hajdúch, Marián and Kleinová, Jana and Holánek, Miloš and Radová, Lenka and Gombošová, Jana and Folber, František},
   article_location = {Heidelberg, Germany},
   article_number = {14},
   keywords = {litihum;akt kinase;chemotherapy;chemoresistance;neutropenia;},
   language = {eng},
   issn = {0941-4355},
   journal = {Support Care Cancer},
   title = {The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard},
   volume = {2006},
   year = {2006}
}

TY  - JOUR
ID  - 752227
AU  - Svoboda, Marek - Hajdúch, Marián - Kleinová, Jana - Holánek, Miloš - Radová, Lenka - Gombošová, Jana - Folber, František
PY  - 2006
TI  - The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard
JF  - Support Care Cancer
VL  - 2006
IS  - 14
SP  - 605-606
EP  - 605-606
PB  - Springer-Verlag
SN  - 09414355
KW  - litihum;akt kinase;chemotherapy;chemoresistance;neutropenia;
N2  - Introduction: Lithium is an antimanic agent successfully used in the treatment of patients with bipolar disorder. Even at therapeutic levels many patients experience one of the most frequent non-toxic and reversible side effect of lithium: leukocytosis. Due this effect, lithium has been used in the treatment and prophylaxis of CIN before the availability of colony-stimulating factors (CSF) and it remains as a costeffective option compared with CSF. Recently, lithium has been reported to protect cells against apoptosis via a direct inhibition of GSK-3beta and activation of Akt/PKB. Both kinases play important role in processes of primary and inducible tumor chemoresistance. Results: I. 151 MTT tests were performed for in-vitro testing of chemo-sensitivity of 53 primary tumours against cisplatin, melphalan, doxorubicin and paclitaxel with or without presence of 10mM or 2mM lithium. At the concentration of 10mM, lithium enormously increased chemoresistance of primary tumours against doxorubicin (p=0,000000453) and paclitaxel (p=0,000277692). At the concentration of 2mM the lithium significantly increases chemoresistance only against doxorubicin. There was no effect of lithium on alkylating agents. II. A retrospective analysis of clinical data of 271 patients who developed CIN and were treated by lithium carbonate (1st group) or without any treatment (2nd group) was done. Median of neutrophils counts at the initial blood counts examinations after chemotherapy was 0,9 and 0.94x109/L (1st and 2nd group respectively) and after 7 days of lithium administration was 2,71x109/L compared to 2,03x109/L at the 2nd group (p=0,15). Conclusions: This study demonstrates: I) lithium can increase chemoresistance of primary tumours against cytostatic agents and II) the effect of lithium on the neutrophils counts is disputative. Therefore there is no rationalization for the use of lithium in the treatment and prophylaxis of CIN. Acknowledgements: The work was supported by grants from The Czech T.Fox Run 2005 and IGA MZCR NR/8335-3.
ER  -

SVOBODA, Marek, Marián HAJDÚCH, Jana KLEINOVÁ, Miloš HOLÁNEK, Lenka RADOVÁ, Jana GOMBOŠOVÁ a František FOLBER. The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard. \textit{Support Care Cancer}. Heidelberg, Germany: Springer-Verlag, 2006, roč.~2006, č.~14, s.~605-606. ISSN~0941-4355.

Podrobný výpis o publikaci